Pravastatin Improves Insulin Resistance in Dyslipidemic Patients

DOI Web Site 5 Citations 40 References
  • Okada Kyoko
    Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Maeda Naoyasu
    Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Kikuchi Kensuke
    Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Tatsukawa Masafumi
    Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Sawayama Yasunori
    Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Hayashi Jun
    Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan. Department of Environmental Medicine and Infectious Diseases, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

Search this article

Abstract

To evaluate the effect of pravastatin on both lipid and glucose metabolism, twenty-two consecutive dyslipidemic patients treated with pravastatin at 10 mg/day for one year were enrolled in this study. The meal test, which consisted of 115 g of cookies (energy 560 kcal; glucose 75 g; protein 7 g; fat 24 g), was conducted before and after one year of treatment. Insulin resistance was assessed by the homeostasis model assessment of insulin resistance (HOMA-IR), by the area under the IRI curve (AUC-IRI), and by the formula AUC-IRI × AUC-PG. After one year of treatment with pravastatin, the plasma glucose (PG), immunoreactive insulin (IRI) and C-peptide levels were unchanged after fasting and at 120 minutes after the meal test; however, PG, IRI and C-peptide levels at 60 minutes after the meal were all significantly decreased from baseline (p < 0.05). AUC-IRI and AUC-IRI × AUC-PG were also significantly decreased (p < 0.05). HOMA-IR was reduced by 26.8%, but the reduction was not significant. The triglyceride (TG) level was decreased after fasting and increased at 60 and 120 minutes after the meal test, but not significantly. This study demonstrated that pravastatin not only reduced serum lipids, but also improved the glucose metabolism, including insulin resistance, of dyslipidemic patients.

Journal

Citations (5)*help

See more

References(40)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top